Hostname: page-component-586b7cd67f-2plfb Total loading time: 0 Render date: 2024-11-30T21:21:12.863Z Has data issue: false hasContentIssue false
  • English
  • Français

Milnacipran et trouble obsessionnel-compulsif: étude d'un cas

Published online by Cambridge University Press:  28 April 2020

P Papart  and
M Ansseau
P Papart
Affiliation:
Unité de psychiatrie, centre hospitalier universitaire du Sart-Tilman, B-4000 Liège 1, Belgique
M Ansseau
Affiliation:
Unité de psychiatrie, centre hospitalier universitaire du Sart-Tilman, B-4000 Liège 1, Belgique
Get access

Résumé

Le trouble obsessionnel-compulsif est une affection grave et difficile à traiter. Plusieurs études récentes ont montré une efficacité de certains antidépresseurs, particulièrement sérotoninergiques. Cependant, certains travaux plaident également pour un rôle des voies noradrénergiques. Nous discutons ici l'essai d'un nouvel antidépresseur, le milnacipran, à action noradrénergique et sérotoninergique, chez une patiente atteinte d'un trouble obsessionnel-compulsif rebelle. Le rôle possible de la médication dans la très nette amélioration de la symptomatologie obsessionnelle et dépressive est discuté.

Summary

Summary

Obsessive-compulsive disorder is a severe pathology which is difficult to treat. Several recent studies have shown the efficacy of some antidepressants, particularly of the serotonergic type. Other findings, however, suggest a role for the noradrenergic neurotransmission. We present a trial using a new antidepressant, milnacipran, with both noradrenergic and serotonergic activity, in a patient presenting treatment-resistant obsessive compulsive disorders. The role of the drug in the marked improvement of the patient's symptomatology is discussed.

Keywords

milnaciprantrouble obsessionnel-compulsifmilnacipranobsessive compulsive disorder
Type
Fait clinique
Information
Psychiatry and Psychobiology , Volume 5 , Issue 5 , 1990 , pp. 325 - 327
Copyright
Copyright © European Psychiatric Association 1990

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

*

Travail réalisé dans le cadre du programme «Erasmus» European Certificate in Anxiety Disorders (Maastricht, Caen et Oxford, 1989).

References

Références

Ansseau, M, von Frenckell, R, Cerfontaine, JL, Papart, P, Franck, G, Timsit-Berthier, M, Geenen, V, Legros, JJ (1988) Blunted response of growth hormone to clonidine and apomorphine in endogenous depression. Br J Psychiatry 153, 65–71CrossRefGoogle ScholarPubMed
Ansseau, M, von Frenckell, R, Mertens, C, De Wilde, J, Botte, L, Devoitille, JM, Evrard, JL, De Nayer, A, Darimont, P, Dejaiffe, G, Mirel, J, Meurice, E, Parent, M, Couzinier, JP, Demarez, JP, Serre, C (1989a) Controlled comparison of two doses of milnacipran (F 2207) and amitriptyline in major depressive patients. Psychopharmacol 98, 163–168CrossRefGoogle Scholar
Ansseau, M, von Frenckell, R, Papart, P, Mertens, C, De Wilde, J, Botte, L, Devoitille, JM, Evrard, JL, De Nayer, A, Koch-Bourdouxhe, S, Darimont, P, Lecoq, A, Mirel, J, Couzinier, JP, Demarez, JP, Serre, C (1989b) Controlled comparison of milnacipran (F 2207) 200 mg and amitriptyline in endogenous depressive patients. Hum Psychopharmacol 4, 221–227CrossRefGoogle Scholar
Carroll, BJ, Feinberg, M, Smouse, PE, Rawson, SG, Greden, JF (1981) The Carroll rating scale for depression. I. Development, reliability and validation. Br J Psychiatry 138, 194–200CrossRefGoogle Scholar
Cottraux, J, Mollard, E, Bouvard, M, Marks, I, Sluys, M, Nury, AM, Douge, R, Cialdella, P (1990) A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 5, 17–30CrossRefGoogle ScholarPubMed
Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, HS (1989) Efficacy of fluvoxamine in obsessive–compulsive disorder. A double-blind comparison with placebo. Arch Gen Psychiatry 46, 36–44CrossRefGoogle ScholarPubMed
Hollander, E, Fay, M, Cohen, B, Campeas, R, Gorman, JM, Liebowitz, MR (1988) Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder : behavioral findings. Am J Psychiatry 145, 1015–1017Google ScholarPubMed
Montgomery, SA, Montgomery, DB (1980) Measurement of change in psychiatric illness : new obsessional, schizophrenia and depression scales. Postgrad Med J 56, 50–52Google ScholarPubMed
Moret, C, Charveron, M, Finberg, JPM, Couzinier, JP, Briley, M (1985) Biochemical profile of midalcipran (F 22077, 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24, 1211–1219CrossRefGoogle Scholar
Wom Kim, S, Dysken, MW (1988) A review of serotonin re-uptake inhibitors in obsessive-compulsive disorder. Psychiatr Ann 18, 373–380CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.